Form 4: Nuvectis Pharma Director Matthew Kaplan Receives Restricted Stock Grant

Nuvectis Pharma, Inc. Director Matthew L. Kaplan was granted 30,000 shares of restricted common stock, vesting over three years, as part of his compensation.

Summary

• Matthew L. Kaplan, a Director of Nuvectis Pharma, Inc. (NVCT), acquired 30,000 shares of common stock on June 12, 2025.
• The shares were granted at a price of $0, indicating a restricted stock award rather than a purchase.
• These 30,000 shares are restricted common stock and will vest in equal annual installments over three years.
• Vesting is contingent upon Mr. Kaplan's continued service on the Company's Board of Directors on the respective vesting dates.
• Following this transaction, Mr. Kaplan beneficially owns a total of 113,760 shares of Nuvectis Pharma common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While not a major financial event, the grant of restricted stock to a director is a standard practice that aligns management's interests with shareholders, which is generally viewed favorably. It indicates stability in governance and a commitment to long-term value creation.

Positives

• The grant of restricted stock aligns the director's long-term interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a common and effective way to incentivize directors to contribute to the company's sustained growth and success.

Negatives

• The shares are restricted and do not provide immediate liquidity to the director.
• The vesting schedule means the director must remain on the board for three years to fully realize the value of the grant.

Risks

• The vesting of the restricted stock is subject to Mr. Kaplan's continued service on the Company's Board of Directors, meaning forfeiture if service ceases before full vesting.

Future Outlook

The grant of restricted stock with a three-year vesting schedule implies an expectation of continued service from Director Matthew L. Kaplan, aligning his future contributions with the company's performance over this period.

Management Comments

• The transaction reflects a standard equity grant to a director, aligning their interests with long-term shareholder value.

Industry Context

Equity grants, particularly restricted stock units (RSUs) or restricted stock, are a common form of compensation for non-employee directors across various industries, including the pharmaceutical and biotechnology sectors. This practice aims to align the interests of the board members with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The use of restricted stock as director compensation is a standard practice in the U.S. public company landscape, particularly prevalent in growth-oriented sectors like biotechnology.
• The three-year vesting schedule is typical for such grants, comparable to similar compensation structures observed at companies like Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors, aiming for long-term retention and alignment.
• The grant price of $0 is standard for equity awards that are not purchased but granted as compensation.

Corporate Governance

Related Party Transactions

• The grant of 30,000 shares of restricted common stock to Matthew L. Kaplan, a Director of Nuvectis Pharma, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the long-term performance of the company, potentially leading to more shareholder-friendly decisions.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• Matthew L. Kaplan's continued service on the Board of Directors for the next three years to ensure full vesting of the restricted stock.

Key Dates

Recommendation

Keywords

Nuvectis Pharma, NVCT, Form 4, Insider Transaction, Stock Grant, Restricted Stock, Director Compensation, Equity Award, Beneficial Ownership